Olga Lamacchia
Overview
Explore the profile of Olga Lamacchia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pezzilli S, Tohidirad M, Biagini T, Scarale M, Alberico F, Mercuri L, et al.
Diabetes Metab
. 2022 Apr;
48(5):101353.
PMID: 35487478
Aim: This study investigated whether rare, deleterious variants in monogenic diabetes-genes are associated with early-onset type 2 diabetes (T2D). Methods: A nested case-control study was designed from 9712 Italian patients...
12.
Morieri M, Lamacchia O, Manzato E, Giaccari A, Avogaro A
Cardiovasc Diabetol
. 2022 Apr;
21(1):57.
PMID: 35473579
Background: Greater efforts are needed to overcome the worldwide reported low achievement of LDL-c targets. This survey aimed to dissect whether and how the physician-based evaluation of patients with diabetes...
13.
Rigoli L, Caruso V, Aloi C, Salina A, Maghnie M, DAnnunzio G, et al.
Int J Environ Res Public Health
. 2022 Feb;
19(4).
PMID: 35206658
Wolfram syndrome 1, a rare autosomal recessive neurodegenerative disease, is caused by mutations in the gene. It is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD), and...
14.
Pezzilli S, Mazza T, Scarale M, Tang Y, Andreozzi F, Baroni M, et al.
Acta Diabetol
. 2022 Feb;
59(5):747-750.
PMID: 35112188
No abstract available.
15.
Correale M, Mazzeo P, Mallardi A, Leopizzi A, Tricarico L, Fortunato M, et al.
Cardiovasc Drugs Ther
. 2021 Sep;
36(6):1157-1164.
PMID: 34519913
Purpose: The use of sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) was associated in previous studies with an improved vascular function in non-human experimental models. We therefore sought to evaluate possible changes in endothelial...
16.
Correale M, Lamacchia O, Ciccarelli M, Dattilo G, Tricarico L, Brunetti N
Heart Fail Rev
. 2021 Aug;
28(3):733-744.
PMID: 34379224
Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of...
17.
Scarale M, Antonucci A, Cardellini M, Copetti M, Salvemini L, Menghini R, et al.
J Clin Endocrinol Metab
. 2021 Jun;
106(11):e4350-e4359.
PMID: 34192323
Context: Type 2 diabetes (T2D) shows a high mortality rate, partly mediated by atherosclerotic plaque instability. Discovering novel biomarkers may help identify high-risk patients who would benefit from more aggressive...
18.
Copetti M, Biancalana E, Fontana A, Parolini F, Garofolo M, Lamacchia O, et al.
Acta Diabetol
. 2021 May;
58(10):1425-1428.
PMID: 34050821
Aims: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very...
19.
Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al.
BMC Med
. 2021 Mar;
19(1):66.
PMID: 33715620
Background: It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR...
20.
Lamacchia O, Sorrentino M
Curr Vasc Pharmacol
. 2020 Mar;
19(2):233-240.
PMID: 32183678
Type 2 diabetes mellitus (T2DM) is a rapidly evolving global health issue associated with a markedly increased risk of cardiovascular (CV) morbidity and mortality. The hyperglycaemic milieu contributes to the...